Moderna +177%, Merck +13% on Melanoma Vaccine Phase 3 Win
Moderna soared 177% and Merck jumped 13% on Aug 19 after intismeran plus Keytruda hit its primary endpoint in the Phase 3 INTerpath-001 melanoma trial.
mrna stock
Moderna soared 177% and Merck jumped 13% on Aug 19 after intismeran plus Keytruda hit its primary endpoint in the Phase 3 INTerpath-001 melanoma trial.